Patent details

Basic Information

Publication number:

EP3013335

PCT Application Number:

JP2014067723

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP147399711

PCT Publication Number:

WO2014208774

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING ERIBULIN AND LENVATINIB

French Title of Invention:

POLYTHÉRAPIE DESTINÉE AU TRAITEMENT DU CANCER CONTENANT D'ÉRIBULINE ET DU LENVATINIB

German Title of Invention:

KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON KREBS ENTHALTEND ERIBULIN UND LENVATINIB

SPC Number:

Dates

Filing date:

26/06/2014

Grant date:

07/11/2018

EP Publication Date:

04/05/2016

PCT Publication Date:

31/12/2014

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

07/11/2018

EP B1 Publication Date:

07/11/2018

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

26/06/2019

Expiration date:

26/06/2034

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

31/10/2018

 

 

Name:

Eisai R&D Management Co., Ltd.

Address:

6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088, Japan (JP)

Inventor

1

Name:

NOMOTO, Kenichi

Address:

United States (US)

2

Name:

WU, Jiayi

Address:

United States (US)

Priority

Priority Number:

201361839542 P

Priority Date:

26/06/2013

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/357; A61K 31/47; A61K 45/06; A61P 35/00; A61P 35/02; A61P 35/04;

Publication

European Patent Bulletin

Issue number:

201845

Publication date:

07/11/2018

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages